We have unceasingly strived to realize our corporate philosophy of always making a contribution to human health.
Kyorin will continue to take on challenges and will evolve to become a company supporting healthy lifestyles through our business in the treatment and prevention of disease and the maintenance and promotion of good health.
Company history
Product history
1920～
1923
Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.
1931
Kyorin Chemical Laboratory was established.
1940
Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.
1947
The Okaya Plant was started
1950～
1957
The medical journal bulletin “Doctor Salon” was started.
1961
Behyd, a diuretic and antihypertensive agent, was launched.
1962
Kyorin Chemical Laboratory (later Technical Center of Development) was established.
1965
The Head Office was completed in Kanda Surugadai.
1965
KYORIN AP-2, an analgesic, was launched.
Deamelin-S, an oral hypoglycemic agent, was launched.
1967
The Nogi Plant was opened.
1971
Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.
1974
Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.
1977
Central Research Laboratories were opened.
1980～
1980
Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).
1981
Mucodyne, a mucoregulant, was launched.
1984
Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.
1989
Ketas, for bronchial asthma and cerebrovascular disorders, was launched.
Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.
1992
KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.
1993
Megalocin (FLRX), a long-acting new quinolone agent, was launched.
1995
The Noshiro Plant was opened.
1996
A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.
The Research Center (now the WATARASE Research Center) was founded.
1996
Pentasa, a treatment for ulcerative colitis and Crohn’s disease, was launched.
1996
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).
1998
Milton, an effervescent disinfectant business, was acquired from P&G.
1999
Listed on the Tokyo Stock Exchange, Second Section.
2000
Listed on the Tokyo Stock Exchange, First Section.
2000～
2000
Gatifloxacin eyedrops was licensed to Allergan (U.S.A.).
2001
A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.
2001
Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
2002
A subsidiary company, Kyorin Europe GmbH (Germany), was established.
2002
Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.
2004
ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.
2005
The stock of Toyo Pharma Co., Ltd. (present KYORIN Rimedio Co., Ltd.) was acquired, making it into a subsidiary company.
2006
The Nogi Plant was closed.
2006
The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.
2007
Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.
2008
KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.
2010
KYORIN Co., Ltd. changed its name to KYORIN Holdings, Inc.
2010～
2012
Acquisition (conversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities Co., Ltd.
2012
RUBYSTA, a multi-purpose disinfectant cleaner, was launched.
2013
Head office moved to Ochanomizu sola city in Kanda Surugadai.
2013
Flutiform, a combination drug for asthma treatment, was launched.
2015
Establishment of the WATARASE Research Center of KYORIN Pharmaceutical Co., Ltd. through consolidation of the Drug Discovery Center (the former Central Research Laboratories) and the R&D Center (the former Research Center).
2015
Eklira Genuair, a treatment for COPD, was launched.
FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.)
2016
The Okaya Plant was closed
2016
Montelukast tablets 10mg, 5mg「KM」, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
DESALEX Tablets 5mg a treatment of allergic diseases drug was launched
2017
KYORIN Rimedio Co., Ltd.’s Takaoka Pharmaceutical Technology Innovation Center was established.
2018
New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Tokyo), commences operations.
2018
Beova Tablets 50mg a treatment of OAB drug was launched
2019
GeneSoC®, a microchannel-based genetic measurement device, was launched.
2020
KYORIN Pharmaceutical Group Facilities Co., Ltd. and KYORIN Medical Supply Co., Ltd. merge.
2020
Lasvic Tablets 75mg an oral quinolone antibacterial agent was launched
2021
Lasvic Intravenous Drip Infusion Kit 150mg an injectable new quinolone antibacterial agent was launched
Zymso Intravesical Solution 50%, an interstitial cystitis treatmet was launched
GeneSoC® mini was launched.
2022
Lyfnua® Tablets 45mg Selective P2X3 receptor antagonist/Refractory chronic cough was launched
